[Table_Reportdate] 2025年04月01日 超配 [证券分析师 Table_Authors] 姚星辰 S0630523010001 yxc@longone.com.cn 联系人 吴康辉 wkh@longone.com.cn -30% -20% -10% 0% 10% 20% 30% 2024-03 2024-05 2024-07 2024-09 2024-11 2025-01 2025-03 食品饮料(申万) 沪深300 [相关研究 table_product] 3.政策力度加码，板块情绪回暖—— 食 品 饮 料 行 业 周 报 （ 2025/3/10- 2025/3/16） [Table_NewTitle 年报陆续发布，关注基本面表现 ] ——食品饮料行业周报（2025/3/24-2025/3/30） [table_main] 投资要点： 行 业 周 报 食 品 饮 料 1.劲仔食品（003000）：鱼制品势能 强劲，线下渠道稳健增长——公司简 评报告 2.糖酒会符合预期，关注底部机会— —食品饮料行业周报（2025/3/17- 2025/3/23） ➢ 二级市场表现：上周食品饮料板块上涨 ...

[Table_Reportdate] 2025年04月01日 超配 行 业 简 评 [证券分析师 Table_Authors] 陶圣禹 S0630523100002 tsy@longone.com.cn [table_stockTrend] -29% -12% 4% 21% 38% 54% 71% 24-04 24-07 24-10 25-01 申万行业指数:非银金融(0749) 沪深300 [相关研究 table_product] 1. 从西部收购国融，看中小券商把 握并购浪潮下的区域整合持续落地 ——非银金融行业简评 2. 从国信收购万和，看券商并购趋 势从业务互补迈向国资整合——非 银金融行业简评 行 业 研 究 非 银 金 融 3. 从国君合并海通，看头部整合示 范效应下的航母级券商启航——非 银金融行业简评 [Table_NewTitle 从湘财合并大智慧，看 ] 中小券商与金融 科技跨界整合新路径 ——非银金融行业简评 [table_main] 投资要点： 1）庞大的用户基础带来较大的获客空间：湘财证券截至2024H1末仅有67家证券营业部、 4家业务分公司、4家区域分公司、2家全资子公司，客户触 ...

Group 1: Key Recommendations - The report highlights Vanadium Titanium Co., Ltd. (000629) as a key recommendation, indicating that high-end production capacity is being gradually released, suggesting an impending profit turning point [8] - The report notes that the company achieved a revenue of 13.209 billion yuan in 2024, a year-on-year decrease of 8.1%, and a net profit attributable to shareholders of 285 million yuan, down 73.0% year-on-year [8][9] - The report emphasizes the structural changes in downstream demand, with an increase in vanadium demand in non-steel applications, particularly in energy storage [9] Group 2: Industry Insights - The vanadium market is currently experiencing an oversupply, with the average market price of vanadium pentoxide in 2024 at approximately 80,500 yuan per ton, a year-on-year decrease of 25.9% [9] - The titanium dioxide market is also facing oversupply due to weak demand in downstream sectors such as real estate and coatings, with the company’s titanium dioxide revenue in 2024 reaching 3.517 billion yuan, a year-on-year increase of 2.5% [10] - The report forecasts that the company plans to produce 52,500 tons of vanadium products and 22,550 tons of sulfuric acid titanium dioxide in 2025, indicating a focus on expanding production capacity [11] Group 3: Market Performance - The pharmaceutical and biotechnology sector saw an overall increase of 0.98% in the last week, outperforming the CSI 300 index by 0.97 percentage points [12] - The report indicates that the PE valuation for the pharmaceutical and biotechnology sector is currently at 27.11 times, which is at a historically low level [12] - The report suggests that the recent performance of innovative drugs has been strong, with several companies reporting excellent earnings data [14]

Investment Rating - The industry investment rating is "Overweight" for the non-banking financial sector, indicating a positive outlook compared to the broader market [1][35]. Core Insights - The report highlights a mixed performance in the non-banking financial sector, with a slight decline of 0.1% in the non-banking financial index, while the insurance index showed a positive return of 0.63% [4][8]. - The report emphasizes the expected improvement in brokerage firms' performance driven by investment recovery and the emergence of cross-industry collaborations between brokerages and financial technology [4]. - The introduction of the "20 Articles on Pension Finance" by the financial regulatory authority is expected to guide the development of the pension finance sector, enhancing the financial services available to the elderly population [4][33]. Summary by Sections Market Review - The non-banking financial index decreased by 0.1%, while the brokerage index fell by 0.51% and the insurance index rose by 0.63% [4][8]. - Average daily trading volume in the stock market was 14,950 billion, down 16.5% week-on-week [17]. Brokerage Insights - The securities industry is projected to achieve a net profit of 167.3 billion in 2024, a year-on-year increase of 21.3% [4]. - 28 listed brokerages reported a 15.3% increase in net profit, with a significant 96.6% growth in the fourth quarter, attributed to the recovery in the equity market [4]. - The merger of Xiangcai and Dazhihui is expected to create a new path for brokerage and financial technology collaboration, enhancing user growth and business synergy [4]. Insurance Insights - The "20 Articles on Pension Finance" outlines a five-year plan to establish a pension finance system with Chinese characteristics, focusing on multi-level pension insurance [4][33]. - Listed insurance companies reported significant profit growth in 2024, driven by improvements in the equity market and enhanced product value rates [4]. Investment Recommendations - For brokerages, the report suggests focusing on mergers and acquisitions, high asset turnover, and return on equity (ROE) improvements, recommending investment in large, financially robust brokerages [4]. - In the insurance sector, attention is drawn to large comprehensive insurance companies with competitive advantages, supported by new regulatory policies [4].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [34]. Core Insights - The pharmaceutical and biotechnology sector showed a positive market performance, with an overall increase of 0.98% from March 24 to March 28, 2025, ranking first among 31 industries in the Shenwan index and outperforming the CSI 300 index by 0.97 percentage points [11][30]. - Year-to-date, the sector has risen by 3.53%, ranking 12th among the 31 industries, and has outperformed the CSI 300 index by 4.03 percentage points [16][30]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 27.11 times, which is at a historically low level, with a valuation premium of 126% compared to the CSI 300 index [21][30]. - Notable sub-sectors that performed well include chemical pharmaceuticals and biological products, with increases of 4.04% and 1.17%, respectively [11][30]. Market Performance - The report highlights that 226 stocks (47.68% of the sector) increased in value last week, with the top five performers being Yihe Jiaye (28.58%), Rundu Co. (21.83%), Zhixiang Jintai-U (18.34%), Hehua Co. (16.22%), and Rongchang Bio (15.38%) [28][30]. - Conversely, 235 stocks (49.58% of the sector) experienced declines, with the largest drop being ST Xiangxue at -40.82% [28][30]. Industry News - A significant policy change was announced by six government departments, including the National Health Commission and the Ministry of Finance, which will eliminate outpatient prepayment fees in public medical institutions starting March 31, 2025, and standardize inpatient prepayment management [30][31]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector currently presents significant investment opportunities, particularly in innovative drugs, medical services, chain pharmacies, medical devices, and branded traditional Chinese medicine [5][32]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Nuotai Bio, while stocks to watch include Tebao Bio, Kelun Pharmaceutical, International Medical, Kaili Medical, and Baipusais [5][32].

Investment Strategy and Key Stock Portfolio - The report indicates that the effects of policies are becoming evident, with a gradual shift in the internal and external demand pattern expected to manifest in the second quarter of 2025. Domestic retail sales and fixed asset investment are showing steady improvement, while export growth is declining more significantly than imports, suggesting continued support for GDP from net exports in the first quarter [4][9]. - The report highlights that the performance verification period is underway, with corporate profit growth showing a year-on-year decline in January-February. Revenue growth is also slowing, and profit margins are experiencing seasonal declines. However, profit growth is expected to continue its recovery trend, influenced by the pace and intensity of policy implementation [4][10]. - The report notes an increased risk of stagflation in the U.S., which may affect global market risk appetite. The impending implementation of reciprocal tariffs could have significant impacts on regions outside of China, potentially escalating trade tensions and increasing the likelihood of U.S. stagflation or recession [4][10]. Key Stock Recommendations - The report lists a portfolio of recommended stocks for April 2025, including companies such as Satellite Chemical (002648.SZ), Hengli Petrochemical (600346.SH), and Betta Pharmaceuticals (300558.SZ), among others. Each company is selected based on its industry position and growth potential [3][11]. - Satellite Chemical is highlighted for its integrated industrial chain advantages and its leading position in domestic high-end new materials, with expectations for performance improvement as raw material costs stabilize and market demand recovers [12]. - Hengli Petrochemical is noted for maintaining high growth in the first three quarters of 2024, with strong profitability under high oil prices and a favorable dividend rate, indicating its long-term cash flow stability [12][13]. - Betta Pharmaceuticals is recognized for its innovative drug pipeline and market share growth, particularly in the non-small cell lung cancer sector, with several products gaining rapid market acceptance [12][13]. - The report emphasizes the importance of focusing on sectors with strong certainty in structural market conditions, such as consumer and high-tech industries, while also considering high-dividend sectors in the short term [10]. ETF Recommendations - The report includes recommendations for ETFs, such as Huatai-PB CSI 300 ETF (510300.OF) and Haitong CSI Major Consumer ETF (159928.OF), which are expected to track their respective indices effectively [14]. - The report suggests that these ETFs may provide exposure to sectors that are likely to benefit from the ongoing economic recovery and structural shifts in the market [14].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [34]. Core Insights - The pharmaceutical and biotechnology sector showed a positive market performance, with an overall increase of 0.98% from March 24 to March 28, 2025, ranking first among 31 industries in the Shenwan index and outperforming the CSI 300 index by 0.97 percentage points [11][30]. - Year-to-date, the sector has risen by 3.53%, ranking 12th among the 31 industries, and has outperformed the CSI 300 index by 4.03 percentage points [16][30]. - The current price-to-earnings (PE) ratio for the sector is 27.11, which is at a historically low level, with a valuation premium of 126% compared to the CSI 300 index [21][30]. - Notable sub-sectors that performed well include chemical pharmaceuticals and biological products, with increases of 4.04% and 1.17%, respectively [11][30]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the fact that 226 stocks (47.68% of the total) increased in value last week, with the top five performers being Yihe Jiaye (28.58%), Rundu Co., Ltd. (21.83%), Zhixiang Jintai-U (18.34%), Hehua Co., Ltd. (16.22%), and Rongchang Biological (15.38%) [28][30]. - Conversely, 235 stocks (49.58% of the total) experienced declines, with the largest drop being ST Xiangxue at -40.82% [28][30]. Industry News - A significant policy change was announced by six government departments, including the National Health Commission and the Ministry of Finance, which will eliminate outpatient prepayment fees in public medical institutions starting March 31, 2025, and standardize inpatient prepayment management [30][31]. - The policy aims to improve the efficiency of hospital billing and enhance the role of medical insurance funds, which is expected to positively impact the industry [30][31]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector currently presents significant investment opportunities, particularly in innovative drugs, medical services, chain pharmacies, medical devices, and branded traditional Chinese medicine [5][32]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Nuotai Biological, while stocks to watch include Tebao Biological, Kelun Pharmaceutical, International Medical, Kaili Medical, and Baipusais [5][32].

Investment Rating - The report rates the non-banking financial industry as "Overweight" [1][35]. Core Insights - The report highlights that the non-banking financial sector is experiencing a recovery, with significant growth in net profits for securities firms and insurance companies driven by improved market conditions and regulatory support [4][33]. - The report emphasizes the potential for mergers and acquisitions in the brokerage industry, particularly with the proposed merger of Xiangcai and Dazhihui, which could create new growth opportunities through a combination of traffic and licensing [4]. - The introduction of the "20 Articles on Pension Finance" by the financial regulatory authority is expected to enhance the development of the pension finance system, providing a solid foundation for the growth of listed insurance companies [4][33]. Market Overview - The non-banking financial index decreased by 0.1% last week, with the brokerage index down by 0.5% and the insurance index up by 0.6%, indicating a divergence in performance within the sector [4][8]. - The average daily trading volume in the stock market was 14,950 billion yuan, a decrease of 16.5% week-on-week, reflecting a slowdown in market activity [4][17]. Securities Industry Analysis - The securities industry is projected to achieve a net profit of 167.3 billion yuan in 2024, representing a year-on-year growth of 21.3%, driven by improvements in brokerage and asset management revenues [4]. - The report notes that 28 listed brokerages have reported a 15.3% increase in net profit, with a significant 96.6% growth in the fourth quarter, attributed to favorable market conditions following policy implementations [4]. Insurance Industry Analysis - The listed insurance companies are expected to report strong performance in 2024, with net profits significantly boosted by improvements in the equity market and enhanced product value rates due to regulatory changes [4]. - The report anticipates that the aging population will create opportunities for the development of pension finance, with measures aimed at improving financial services for the elderly [4]. Investment Recommendations - For the securities sector, the report suggests focusing on mergers and acquisitions, high asset returns, and improving return on equity (ROE), recommending investment in large, financially robust brokerages [4]. - In the insurance sector, the report advises attention to large comprehensive insurance companies that possess competitive advantages, particularly in light of new regulatory frameworks aimed at high-quality development [4].

[Table_Reportdate] 2025年3月31日 标配 行 业 周 报 [Table_Authors] 证券分析师 方霁 S0630523060001 fangji@longone.com.cn 联系人 董经纬 djwei@longone.com.cn [table_stockTrend] [table_product] 相关研究 1.8月国内手机出货量同比上升 26.7%，联想发布多款AIPC新 品 — — 电 子 行 业 周 报 （20240923-20240929） 1. 国内厂商AI投入持续高增，华为 发布全面搭载鸿蒙的首款阔折叠 Pura X——电子行业周报 （2025/3/17-2025/3/23） 2. 北方华创拟取得芯源微控制权， 关注GTC大会带来的AI产业链机遇 ——电子行业周报（2025/3/10- 2025/3/16） 3. AI Agent产品Manus亮相，AI眼 镜驱动消费电子新一轮增长——电 子行业周报（2025/3/3-2025/3/9） [Table_NewTitle] Semicon展会中国半导体设备产业光彩 四溢，存储龙头释放涨价预期 ——电子行业周报2025 ...

公 司 简 评 买入（维持） 报告原因：业绩点评 ——公司简评报告 [Table_Reportdate] 2025年03月31日 [table_main] 投资要点 ➢ 事件：公司发布2024年年度报告，受下游需求疲软影响、公司主营产品市场价格走低，年 度业绩承压，四季度盈利端环比有所改善。2024年全年公司实现营收132.09亿元，同比- 8.1%；归母净利润2.85亿元，同比-73.0%；毛利率7.6%，同比-6.8pct；净利率2.2%，同 比-5.3pct。2024Q4单季度公司实现营收27.35亿元，同比-15.2%、环比-17.5%；归母净利 润1.02亿元，同比-45.9%、环比+122.0%；毛利率10.3%，同比-4.9pct、环比+4.1pct；净 利率3.6%，同比-2.5pct、环比+2.2pct。 电 力 设 备 与 新 能 源 [数据日期 Table_cominfo] 2025/03/28 收盘价 2.89 总股本(万股) 929,497 流通A股/B股(万股) 929,060/0 资产负债率(%) 16.08% 市净率(倍) 2.10 净资产收益率(加权) 1.50 12个月内最 ...